"CMO is the Golden Egg of my practice"
Dr. Christine Doherty N.D. - Milford NH
Dr. Christine Doherty N.D. - Milford NH
Numerous books have been written about the effects of CMO™ on Arthritis
CMO™ has been found through clinical studies and client testimonies to benefit many with autoimmune diseases such as osteoarthritis, rheumatoid arthritis, fibromyalgia, lupus, Crohn’s disease, Sjögren’s syndrome and multiple sclerosis.
|
|
CMO Highlights
|
|
The CMO™ discovery
In 1971, the predecessor of CMO™ capsules, was first discovered by a researcher at the National Institutes of Health. That predecessor was cetyl myristoleate. The researcher was unable to get his project funded and slowly carried on at his own expense. Eventually he discovered that when this substance was injected near the joints of lab animals it brought amazing results. Many years later he experienced the same benefit on his body. After his doctor could provide no further relief through conventional medicine, he successfully injected himself cetylmyristoleate on the knees. His doctor was so amazed at the beneficial results, he urged him to publish a report.
In March of 1994, that report about injectable cetyl myristoleate was published in The Journal of Pharmaceutical Sciences. In the report, the researcher expressed his hope that other studies would be conducted, "particularly, more extensive tests of cetyl myristoleate analogues.”In late 1994, the International Immunological Center of The San Diego Clinic research staff did exactly what that researcher had hoped for. They developed an orally administered nutritional supplement. This dietary supplement is an analogue called CMO™, a trade name for cerasomal-cis-9-cetylmyristoleate. The San Diego Clinic did the first clinical study on CMO™, which study demonstrated CMO™ to be an outstanding product.
In December 1995, CMO™ was introduced in Nevada to the medical community at the National Medical Conference on Aging. Five doctors afflicted with a variety of conditions tried CMO™. All five doctors responded well within three days. CMO™ became star of the conference resulting ultimately in hundreds of doctors using CMO™ for their patients.In February 1996, after successful reports from the medical community, CMO™ became available to the public. Beneficial effects of CMO™ inspired several books about the subject. Dr Sands had numerous radio interviews and the attention of newspapers and magazines.
In 1971, the predecessor of CMO™ capsules, was first discovered by a researcher at the National Institutes of Health. That predecessor was cetyl myristoleate. The researcher was unable to get his project funded and slowly carried on at his own expense. Eventually he discovered that when this substance was injected near the joints of lab animals it brought amazing results. Many years later he experienced the same benefit on his body. After his doctor could provide no further relief through conventional medicine, he successfully injected himself cetylmyristoleate on the knees. His doctor was so amazed at the beneficial results, he urged him to publish a report.
In March of 1994, that report about injectable cetyl myristoleate was published in The Journal of Pharmaceutical Sciences. In the report, the researcher expressed his hope that other studies would be conducted, "particularly, more extensive tests of cetyl myristoleate analogues.”In late 1994, the International Immunological Center of The San Diego Clinic research staff did exactly what that researcher had hoped for. They developed an orally administered nutritional supplement. This dietary supplement is an analogue called CMO™, a trade name for cerasomal-cis-9-cetylmyristoleate. The San Diego Clinic did the first clinical study on CMO™, which study demonstrated CMO™ to be an outstanding product.
In December 1995, CMO™ was introduced in Nevada to the medical community at the National Medical Conference on Aging. Five doctors afflicted with a variety of conditions tried CMO™. All five doctors responded well within three days. CMO™ became star of the conference resulting ultimately in hundreds of doctors using CMO™ for their patients.In February 1996, after successful reports from the medical community, CMO™ became available to the public. Beneficial effects of CMO™ inspired several books about the subject. Dr Sands had numerous radio interviews and the attention of newspapers and magazines.
There are obstacles to overcome in the part of the user. The consumption of caffeine, chocolate and alcoholic beverages during the treatment block our product. Also the presence of hard drugs such as methotrexate which act as immune suppressants have asimilar effect of blockade. Cortisones block partially. Please see the Dosing/Guidelines tab for further information.